By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Gulf PressGulf Press
  • Gulf News
    • Saudi Arabia
    • UAE
    • Oman
    • Kuwait
    • Qatar
    • Bahrain
  • Business
  • Technology
  • Real Estate
  • Sport
  • Travel
  • Lifestyle
  • Rankings
  • Explained
  • Opinion
Search
Countries
More Topics
Site Links
  • Newsletter
  • Terms
  • About Us
  • Advertise with us
  • Contact Us
© 2023 Gulf Press. All Rights Reserved.
Reading: UAE Approves Rinvoq as First Oral Vitiligo Treatment Worldwide
Share
Notification Show More
Latest News
Saudi Arabia Champions Development of Arab League Educational Initiatives
Saudi Arabia
Sheikh Nahyan and Sheikh Khalifa Celebrate UAE University Golden Jubilee
UAE
Northern Ibra Health Complex Opens with 1.6 Million Rial Investment
Oman
2025-2026 Audit Report Reveals 1052 Key Recommendations
Bahrain
Kuwait Champions Social Support for Women, Disabled, and Seniors
Kuwait
Aa
Gulf PressGulf Press
Aa
  • Gulf News
  • Business
  • Technology
  • Real Estate
  • Sport
  • Travel
  • Lifestyle
  • Rankings
  • Explained
  • Opinion
Search
  • Gulf News
    • Saudi Arabia
    • UAE
    • Oman
    • Kuwait
    • Qatar
    • Bahrain
  • Business
  • Technology
  • Real Estate
  • Sport
  • Travel
  • Lifestyle
  • Rankings
  • Explained
  • Opinion
Have an existing account? Sign In
Follow US
  • Terms
  • About Us
  • Advertise with us
  • Contact Us
© 2023 Gulf Press. All Rights Reserved.
Gulf Press > Gulf News > UAE > UAE Approves Rinvoq as First Oral Vitiligo Treatment Worldwide
UAE

UAE Approves Rinvoq as First Oral Vitiligo Treatment Worldwide

Mohamed Mahmoud
Last updated: 2026/08/23 at 11:03 PM
Mohamed Mahmoud
Share
5 Min Read
SHARE

Renfoc approved for non-segmental vitiligo in UAE

The Emirates Medicines Authority has approved Renfoc (opadacitinib) for the treatment of non-segmental vitiligo in adults and adolescents aged 12 years and older, the regulator said on its official X account. The decision covers patients whose clinical condition requires systemic, blood-delivered medication and makes Renfoc the first oral therapy licensed for this patient group in the country.

Key details of the Renfoc approval and prescribing information

According to the regulator’s announcement, Renfoc is administered once daily by mouth, providing an additional oral option for eligible patients under established medical criteria. Furthermore, the approval specifies use for those whose disease severity or distribution warrants systemic treatment rather than topical or light-based therapies.

Officials noted that prescribing should follow accepted clinical guidelines and that physicians will determine patient eligibility based on individual medical assessment. Meanwhile, health providers are expected to follow monitoring protocols aligned with the medicine’s safety profile and manufacturer guidance.

Why this decision matters for vitiligo treatment

This approval expands the therapeutic landscape for vitiligo treatment in the UAE by adding an oral therapy to existing topical agents and phototherapy options. Previously, patients who needed systemic intervention often had limited oral or injectable alternatives; therefore, the new licensing could change care pathways for moderate to extensive disease.

In addition, the regulator’s move may influence physician prescribing practices and patient access by recognizing an evidence-based systemic option. Health experts say broader choices can improve individualized treatment plans and patient adherence, particularly for adolescents and adults who seek convenient, once-daily regimens.

Safety profile, eligibility and clinical context

The Emirates Medicines Authority emphasized that Renfoc is intended for patients meeting specific medical criteria and that clinicians should weigh benefits against potential risks. Official guidance suggests that eligible patients undergo baseline assessment and periodic monitoring as clinically indicated, consistent with the management of systemic dermatology treatments.

Furthermore, clinicians are advised to discuss expected outcomes and side effects with patients and caregivers, especially for adolescents. For context, standard vitiligo management also includes topical corticosteroids, calcineurin inhibitors, and phototherapy, and systemic options are reserved for cases where these approaches prove insufficient.

What patients should discuss with their healthcare provider

Patients considering Renfoc should ask about eligibility, expected timelines for repigmentation, safety monitoring, and how the medication fits within an overall treatment plan. Additionally, caregivers of adolescent patients should review dosing, potential interactions, and follow-up schedules as part of shared decision-making.

UAE’s role as an early adopter and implications for access

With this approval, the UAE becomes the first country to expand the licensed use of Renfoc for non-segmental vitiligo in this patient population, according to the regulator’s statement. Observers say the decision highlights the country’s willingness to adopt recent pharmaceutical innovations and streamline availability for patients.

However, wider patient access will depend on subsequent steps, including distribution by manufacturers, inclusion on formularies, and reimbursement decisions by insurers and health authorities. Therefore, the practical impact for patients will unfold as healthcare providers and payers implement the new indication.

What to watch next

Healthcare providers, patient groups and payers are expected to monitor publication of local clinical guidance and real-world outcomes following rollout. In the near term, readers should watch for announcements on product availability in clinics and hospitals, reimbursement updates, and any additional guidance from the Emirates Medicines Authority.

Finally, clinicians and patients will likely seek peer-shared experiences and registry data to better understand long-term effects and comparative effectiveness in routine practice. Therefore, follow-up reports and professional society recommendations will be important to inform ongoing care decisions.

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
[mc4wp_form]
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share this Article
Facebook Twitter Copy Link Print
Previous Article Nasser Science and Technology Develops Smart Spend Analysis Platform for Bapco Refining
Next Article Saudi-French Partnership Expands Horizons
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stay Connected

235.3k Followers Like
69.1k Followers Follow
56.4k Followers Follow
136k Subscribers Subscribe
- Advertisement -
Ad imageAd image

Latest News

Saudi Arabia Champions Development of Arab League Educational Initiatives
Saudi Arabia November 17, 2026
Sheikh Nahyan and Sheikh Khalifa Celebrate UAE University Golden Jubilee
UAE November 17, 2026
Northern Ibra Health Complex Opens with 1.6 Million Rial Investment
Oman November 17, 2026
2025-2026 Audit Report Reveals 1052 Key Recommendations
Bahrain November 17, 2026

You Might also Like

UAE

Sheikh Nahyan and Sheikh Khalifa Celebrate UAE University Golden Jubilee

November 17, 2026
UAE

Dubai Police Identifies Dangerous Driving Behaviors with Smart Cameras

November 17, 2026
UAE

Abu Dhabi Court Sentences 10 for Hotel Brawl and Video Recording

November 17, 2026
UAE

President and Arab League Secretary-General Discuss Regional Developments

November 16, 2026
UAE

Education Ministry Unveils First Semester Exam Schedules

November 16, 2026
UAE

Abu Dhabi Police Successfully Control Fires in Al Bahya and Al Mafraq

November 16, 2026
UAE

All Insurers Now Required to Cover Organ Transplants Without Time Limit

November 15, 2026
UAE

Uganda Eases Entry Restrictions for Its Citizens

November 15, 2026
//

GulfPress is a modern Gulf media platform delivering trusted news, business insights, technology updates, real estate trends, travel stories, explainers, and rankings from across the GCC and the Middle East.

Quick Link

  • About Us
  • Editorial Policy
  • Corrections Policy
  • Advertise with us
  • Contact Us
  • Privacy Policy
  • Terms of use

How Topics

  • Gulf News
  • Business
  • Lifestyle

Sign Up for Our Newsletter

Subscribe to our newsletter to get our latest news instantly!

[mc4wp_form]

Gulf PressGulf Press
Follow US

© 2023 Gulf Press. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc..

[mc4wp_form]
Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?